
## WHAT IS CLAIMED IS:

- 1. An isolated polynucleotide selected from the group consisting of
- (a) \a polynucleotide encoding a polypeptide having the deduced amino acid sequence of Figure 1 or a fragment, analog or derivative of said polypeptide;
- (b) a polynucleotide encoding a polypeptide having the deduced amino acid sequence of Figure 2 or a fragment, analog or derivative of said polypeptide;
- (c) a polynucleotide encoding a polypeptide having the amino acid sequence encoded by the cDNA contained in ATCC Deposit No. 75875 or a fragment, analog or derivative of said polypeptide; and
- (d) a polynucleotide encoding a polypeptide having the amino acid sequence encoded by the cDNA contained in ATCC Deposit No. 75873 or a fragment, analog or derivative of said polypeptide.
  - 2. The polynucleotides of Claim 1 wherein the polynucleotides are DNA.
  - 3. The polynucleotides of Claim 1 wherein the polynucleotides are RNA.
  - The polynucleotides of Claim 1 wherein the polynucleotides are genomic DNA.
  - A polynucleotide of Claim 2 wherein said polynucleotide encodes a polypeptide having the deduced amino acid sequence of Figure 1.
  - 6. A polynucleotide of Claim 2 wherein said polynucleotide encodes a polypeptide having the deduced amino acid sequence of Figure 2.
  - 7. A polynucleotide of Claim wherein said polynucleotide encode the polypeptide encoded by the cDNA of ATCC Deposit No. 75875.

- 8. A polynucleotide of Claim 2 wherein said polynucleotide encodes the polypeptide encoded by the cDNA of ATCC Deposit No. 75873.
- 9. A polynucleotide of Claim 1 having the coding sequence as shown in Figure 1.
- 10. A polynucleotide of Claim 1 having the coding sequence as shown in Figure 2.
- 11. A polynucleotide of Claim 2 having the coding sequence deposited as ATCC Deposit No. 75875.
- 12. A polynucleotide of Claim 2 having the coding sequence deposited as ATCC Deposit No. 75873.
- 13. A vector containing the DNA of Claim-2.
- 14. A host cell genet/ically engineered with the vector of Claim 13.
- 15. A process for producing a polypeptide comprising: expressing from the host cell of claim 14 the polypeptide encoded by said DNA.
- 16. A process for producing cells capable of expressing a polypeptide comprising genetically engineering cells with the vector of Claim 13.
- 17. An isolated DNA hybridizable to the DNA of Claim 2 and encoding a polypeptide having ICE-LAP-3 activity.
- 18. An isolated DNA hybridizable to the DNA of Claim 2 and encoding a polypeptide Maving ICE-LAP-4 activity.
- A polypeptide selected from the group consisting of (i) a polypeptide having the deduced amino acid sequence of Figure 1 and fragments, analogs and derivatives thereof; (ii) a polypeptide having the deduced amino acid sequence of Figure 2 and fragments, analogs and derivatives thereof; (iii) a polypeptide encoded by the CDNA of ATCC Deposit No. 75875 and fragments, analogs and derivatives of said polypeptide; and (iv) a polypeptide encoded by the cDNA of ATCC Deposit No. 75873 and fragments, analogs and derivatives of said polypeptide.
- 20. A polypeptide of Claim 19 wherein the polypeptide has the deduced amino acid sequence of Figure 1.



- 22. Antibodies against the polypeptides of claim 19.
- 23. An antagonist against the polypeptide of claim 19.
- A method for the treatment of a patient having need of ICE-LAP-3 comprising: administering to the patient a therapeutically effective amount of the polypeptide of claim 19.
- A method for the treatment of a patient having need of ICE-LAP-4 comprising: administering to the patient a therapeutically effective amount of the polypeptide of claim 19.
- 26. A method for the treatment of a patient having need to inhibit ICE-LAP-3 comprising: administering to the patient a therapeutically effective amount of the antagonist of Claim 23.
- 27. A method for the treatment of a patient having need to inhibit ICE-LAP-4 comprising: administering to the patient a therapeutically effective amount of the antagonist of Claim 23.
- 28. The method of Claim 24 wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo.
- The method of Claim 25 wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo.
- 30. A method for detecting abnormal cell growth or the susceptibility to abnormal cell growth in a patient comprising:

isolating nucleic acid sequences encoding ICE-LAP-3 or

4 from a sample derived from a patient; and

detecting a mutation in the nucleic acid sequences encoding ICE-LAP-8 or 4.

Jalos